Foreign founders and internationally mobile employees often hear that French BSPCE are the French equivalent of stock options. That comparison is useful, but incomplete. BSPCE means bons de souscription de parts de créateur d’entreprise: founder business subscription warrants that give an eligible person the right to subscribe for shares at a price fixed when the warrants are granted. The right is not the share itself, and a promise in an offer letter is not a completed grant.

In 2026, the decisive questions are not the beneficiary’s nationality or the language of the employment contract. They are the legal form and tax status of the issuing company, the beneficiary’s precise employment or corporate-office status, the shareholder chain, the extraordinary-general-meeting approval, the valuation and the evidence retained for a future exercise or sale. A cross-border move then adds a second layer: France may tax the French-source part of the employment-related gain while another country taxes the same transaction under its own rules and treaty allocation.

This guide isolates the foreign-founder and foreign-employee angle. It does not replace a review of the plan, the constitutional documents, the employment or management relationship and the applicable tax treaty. It complements the firm’s French company formation and corporate-law resource with a transaction-focused checklist for a BSPCE grant that has to survive both French company-law scrutiny and an international tax audit.

I. Can a French company grant BSPCE to a foreign founder or employee?

A. Which companies and beneficiaries qualify under the 2026 rules?

The short answer is yes, but not simply because the person works for a company connected with France. Article 163 bis G of the French General Tax Code (CGI, Code général des impôts) begins with a category test. It states: “Les sociétés par actions peuvent attribuer des bons de souscription de parts de créateur d’entreprise.” The expression sociétés par actions covers French joint-stock forms such as the SAS (société par actions simplifiée, simplified joint-stock company), the SA (société anonyme, public limited company) and the SCA (société en commandite par actions, partnership limited by shares). A SARL (société à responsabilité limitée, private limited-liability company) is not a joint-stock company for this purpose and cannot use its ordinary SARL shares as the issuer of a French BSPCE plan.

The full eligibility rule is in Article 163 bis G of the CGI, in its version applicable from 21 February 2026. The issuer may grant BSPCE to its salaried personnel, to its directors or officers who are subject to the French tax regime for salaries, and to members of its board of directors, supervisory board or, for an SAS, an equivalent statutory body. That is the key distinction for a foreign founder. A founder who is only a shareholder, investor, adviser or independent contractor does not become eligible merely by holding a large stake or signing a services agreement. The founder needs a qualifying employee relationship or a qualifying corporate office, documented in a way that matches the company’s statutes and the tax and social-security treatment of that office.

A foreign passport is not an exclusion. A non-French resident can therefore be an eligible beneficiary if the corporate and role conditions are satisfied. The analysis is separate from the right to enter France, work in France or act as a company officer. A visa, residence permit, social-security affiliation or payroll question can affect the implementation of the role without changing the BSPCE eligibility test. The company should not use BSPCE paperwork to conceal an undeclared employment relationship, to replace remuneration that should have been paid through payroll or to give an independent contractor an instrument reserved for the statutory categories.

The same article also permits grants to qualifying personnel and officers of certain subsidiaries. For a subsidiary, the issuer must directly hold at least 75% of the capital or voting rights. The 2026 wording extends the mechanism to a qualifying sub-subsidiary where the product of the two direct ownership percentages reaches at least 75%. This matters to a foreign group with a French operating subsidiary: the group chart, not the commercial label used by the human-resources team, determines whether a parent-issued plan can reach the French employee. The current administrative explanation confirms the direct 75% test for grants made from 1 January 2026 in BOFiP-RSA-ES-20-40-10, the French tax administration’s official tax doctrine on the scope of BSPCE.

The issuer must also pass the company tests. For a French issuer, the principal conditions are as follows:

• It must be subject to French corporate income tax, commonly called IS (impôt sur les sociétés).
• At least 15% of its capital must be held directly and continuously by individuals, or by legal entities themselves at least 75% held by individuals, subject to the statutory rules for qualifying investment vehicles.
• It must have been registered with the RCS (registre du commerce et des sociétés, the commercial and companies register) for less than fifteen years.
• If its securities are listed, its market capitalisation must be below €150 million, subject to the statutory grace period after an excess.
• It must not have been formed through a concentration, restructuring, extension or takeover of pre-existing activities, unless the specific statutory exception applies.

The 15% threshold deserves particular attention in an international financing round. A founder may control the business economically through a foreign holding company while the French issuer fails the direct individual-holding test. That is not solved by describing the founder as a “founder” in the plan. The company should map the ownership on the grant date, retain the cap table and financing documents, and record the reason why each qualifying participation is counted or excluded.

A foreign company may also be an issuer under the foreign-company rule in Article 163 bis G. Its registered office must be in a European Union Member State or in a state or territory that has a tax treaty with France containing an administrative-assistance clause against tax fraud or evasion. It must also be subject in that jurisdiction to a tax equivalent to French corporate income tax. The French tax administration summarises the point in its official employee shareholding guidance: “L’attribution des bons doit être réalisée dans les mêmes conditions que si elle était le fait d’une entreprise établie en France.” In practice, a US, Canadian, Swiss, British or Asian parent cannot be treated as eligible without checking the treaty, the equivalent-tax requirement and the plan’s compliance with the French conditions. A French subsidiary issuing its own BSPCE can be a different analysis from a foreign parent issuing an instrument intended to receive the French regime.

Finally, “foreign employee” can describe several different situations. A French subsidiary may employ a US national in France. A French company may employ a person who remains resident and works in another country. A French employee may move abroad after the grant. A group may place the person on a foreign affiliate’s payroll while the French company remains the commercial beneficiary of the work. Those facts can change the applicable tax treaty and the French-source fraction of the gain. They do not remove the need to satisfy the Article 163 bis G role test at the issuer or qualifying group company.

B. What approvals, exercise price and documents must be prepared?

BSPCE are not created by a spreadsheet or by a verbal promise. The warrant issue must be authorised through the corporate decision-making process. Article 163 bis G requires an EGM authorisation and describes the warrants as incessibles, meaning that they cannot ordinarily be transferred, subject to the statutory rules and any valid delegation.

The reference to the French Commercial Code is not decorative. Article L. 225-129 and the related capital-increase provisions place the capital decision with the EGM and regulate a delegation to the board. In an SAS, the company must read those rules together with Article L. 227-1 of the Commercial Code and the SAS articles of association. The statutes determine which body is the equivalent statutory organ and how collective decisions are taken. A foreign group cannot safely copy a US board consent and assume that it replaces the French resolution if the French issuer’s statutes require a different process.

The corporate file should normally contain a coherent sequence:

1. A current extract or registration evidence showing the issuer, its RCS registration date and its legal form. The Kbis, traditionally the official extract from the RCS, is useful evidence, but the Kbis does not by itself prove every BSPCE condition.
2. The latest articles of association and the cap table, together with the ownership chain for a parent, subsidiary or sub-subsidiary beneficiary.
3. The EGM minutes, the board or president delegation if used, the report to the shareholders and, where required, the special report of the statutory auditor (commissaire aux comptes).
4. The individual beneficiary schedule: name, role, employer or office, number of BSPCE, class of shares, exercise price, exercise period and the applicable vesting or performance conditions.
5. The plan rules and any country addendum. The addendum should explain foreign payroll, securities-law, exchange-control, data-protection and tax reporting points without changing the mandatory French corporate terms.
6. The signed grant notice or acceptance, the employment contract or corporate appointment, and a record of the date on which each right vests or becomes exercisable.

The exercise price is fixed at the grant date by the EGM or by the authorised delegated body. Article 163 bis G protects the price against an artificial retroactive discount. When the issuer completed a comparable capital increase in the previous six months, the price normally cannot be below the relevant issue price, subject to the statutory discount for a loss of economic value or differences in rights. The board should therefore preserve the financing term sheet, valuation work, preference structure, liquidation preferences and any material change between the financing round and the BSPCE grant. In a foreign group, currency conversion and the difference between preferred and ordinary shares should be documented, not left to a later tax return.

A plan may impose a vesting schedule, a waiting period, performance conditions, good-leaver and bad-leaver rules, an exercise window and a long-stop expiry date. Those contractual conditions are often more important to the beneficiary than the statutory headline. A founder who resigns, is removed as an officer, changes employing entities or moves to a foreign affiliate must read the exact plan language before assuming that vested warrants remain exercisable. A company’s internal policy cannot override a valid statutory resolution, but a vague offer letter can create an evidentiary dispute when the signed plan says something different.

French case law illustrates the risk. In Cour d’appel de Paris, RG no. 21/00121, the court examined the grant resolution, plan rules and the signed contractual undertaking when assessing a claim after a negotiated departure. It referred to BSPCE that “ne pouvaient en toute hypothèse être exercés” before the contractual three-year point. The decision is not a universal rule that every plan must have a three-year vesting period; it is a warning that the plan and the signed documents determine what the beneficiary knew and what rights had actually matured.

The exercise itself should be treated as a separate closing. The beneficiary delivers the signed subscription bulletin, or bulletin de souscription, within the stated period, pays the exercise price in the required form and receives evidence of the resulting share issue. The company should record the date, number of shares, price per share, payment trail, updated cap table, share register and, if relevant, the shareholder agreement accession. In Cour d’appel de Paris, RG no. 22/02484, the court rejected a claim where the beneficiary did not prove that the subscription bulletin had been delivered before the deadline. An email saying “I wish to exercise” may not be equivalent to the formal act required by the plan.

For a foreign beneficiary, the evidence pack should also include the passport or corporate identity data used in the grant, residential addresses at each relevant date, tax-residence certificates where available, the employing entity, the dates and locations of work, the office appointment and termination documents, and the bank record showing the payment. If the exercise price is paid in a currency other than euros, keep the exchange-rate source and calculation. These details will later help determine whether France can tax a French-source fraction and whether a foreign tax authority sees a salary benefit, a capital gain or another form of compensation.

II. How are BSPCE exercised and taxed when the beneficiary lives or works abroad?

A. What happens at exercise, sale, departure and cross-border move?

The 2026 analysis must separate the grant, the exercise and the later disposal. At grant, the beneficiary receives a non-transferable right and does not yet own the underlying shares. At exercise, the beneficiary pays the fixed price and subscribes for the shares. The exercise gain is the difference between the value of the shares on the exercise date and the acquisition price fixed at grant. The 2026 administrative guidance describes the calculation as “L’avantage salarial (ou gain d’exercice) est égal à la différence entre la valeur des titres souscrits au jour de l’exercice des bons …” in BOFiP-RSA-ES-20-40-40, which applies to titles subscribed from 1 January 2025.

There is then a second possible gain: the difference between the sale price and the value of the shares at exercise. The current BOFiP explains that this net sale gain is taxed under the ordinary regime for securities and rights in Article 150-0 A of the CGI. The practical calculation is therefore:

• Exercise gain: value of the share at exercise minus the BSPCE exercise price fixed at grant.
• Sale gain: sale price minus the value used at exercise, after the applicable expenses and statutory rules.

The two amounts can arise at different times and can be taxed in different countries. The fact that a person has paid cash to exercise does not mean that the shares have no taxable value. Conversely, the fact that the company has announced a financing valuation does not settle the value for every class of shares or every exercise date. For an unlisted French company, the official guidance uses a multi-criteria valuation approach, considering the company’s specific features, net book position, profitability and prospects, and, where appropriate, consolidated financial information. Keep the valuation memo and the assumptions used on the exercise date.

For titles subscribed in exercise of BSPCE from 1 January 2025, the French income-tax regime distinguishes the exercise gain from the later sale gain. Under Article 163 bis G and the 2026 official guidance, the exercise gain is generally subject to the 12.8% flat income-tax rate where the beneficiary has exercised the activity or mandate for at least three years in the issuer or qualifying subsidiary chain. The beneficiary may, in the qualifying case, elect the ordinary salary-tax rules. Where the relevant activity or mandate has lasted less than three years at the statutory reference date, the exercise gain is taxed at 30% without that salary-tax option. The 2026 amendments allow qualifying periods in a qualifying sub-subsidiary to count under the statutory ownership conditions.

The rate rule should not be confused with the date of the tax event. The official BOFiP says that the exercise benefit is determined from the exercise-date value, but that the tax event is the disposition, sale, conversion to bearer form or letting of the shares received after the exercise, with specific rules for a tax-neutral exchange in a merger or similar transaction. In other words, an apparently “cashless” or illiquid plan can still produce a tax issue once the relevant statutory event occurs. The company and the beneficiary should reconcile the plan timeline with the tax timeline rather than relying on the date printed on the grant certificate.

For the ordinary 12.8% rate, Article 200 A of the CGI states: “Le taux forfaitaire mentionné au premier alinéa du présent 1 est fixé à 12,8 %.” The exercise-gain rule is not, however, a promise that the total effective burden will always be 12.8%. Social contributions, a progressive-rate election, a retirement-related fixed allowance, high-income surtaxes, foreign taxes and treaty relief can change the result. The later sale gain is a separate capital-gain calculation under Article 150-0 A and the related provisions, including Article 150-0 D of the CGI for the calculation rules and allowable deductions where applicable.

A move abroad raises the source question. For a person who is not tax-resident in France when the relevant transaction occurs, Article 182 A ter of the CGI provides that French-source benefits under Article 163 bis G “donnent lieu à l’application d’une retenue à la source lors de la cession des titres correspondants”. The withholding is collected by the person or institution responsible for paying the sale proceeds or recording the relevant benefit. The French-source part is not automatically the entire gain. The work performed in France during the reference period, the work performed abroad, the vesting or definitive-acquisition date, the residence at the taxable event and the relevant treaty must be analysed together.

The French tax administration’s guidance for mobile beneficiaries states that the reference period generally runs from grant to the date on which the beneficiary definitively acquires the right to exercise, and that the allocation follows the states in which the remunerated activity was performed, subject to the treaty. This is why the company should preserve work-location records even when the beneficiary’s title or employing entity never changes. A foreign resident who worked in France for part of the vesting period may have a French-source fraction; a person who worked entirely outside France may have a different outcome. The residence on the sale date is relevant, but it does not erase the history of the remunerated work.

The 2026 version of form 2041-E for non-residents is an important administrative document. It states in English: “If non-resident withholding taxes have been levied on your French-source income, you will need to complete supplementary return 2041-E.” The form is not a treaty opinion and does not determine the foreign country’s treatment. It is a reminder that the French filing and withholding trail must be completed even when the beneficiary lives abroad and the sale proceeds pass through a foreign broker.

The United States, the United Kingdom and other jurisdictions may treat an equity award as employment income at exercise, at vesting or at another event. A treaty may allocate employment income by workdays while allocating the post-exercise appreciation under a capital-gain article. The company should therefore prepare a country-by-country matrix before the move or the exercise: event, amount, work location, tax residence, treaty article, withholding agent, return and credit mechanism. An informal statement that “the shares are French” or “the employee is no longer French” is not enough.

Departure and termination require a separate contractual review. Does the plan allow exercise after resignation? Does an officer’s removal end the exercise window? Are unvested warrants cancelled? Is there a good-leaver exception for a transfer to a group company? Does an IPO, sale or merger accelerate vesting? The answer comes from the plan and the corporate resolutions, not from the word BSPCE alone. In Cour de cassation, Social Chamber, appeal no. 18-13.926, the employment dispute included compensation for the lost opportunity to acquire the remaining BSPCE after the employment relationship ended. That type of loss-of-chance analysis is fact-specific, but it shows why termination letters, notice periods and the exercise calendar should be reviewed before signature.

A PEA (plan d’épargne en actions, French equity savings plan) should not be treated as a substitute for cross-border advice. In Conseil d’État, 8th and 3rd chambers sitting together, 8 December 2023, no. 482922, the court observed that “de tels bons ne figurant pas au nombre des emplois énumérés par son I” while distinguishing the warrants from eligible shares acquired on exercise. That decision concerns the PEA rules, not foreign residence or treaty allocation. It does not turn a BSPCE plan into an internationally portable tax shelter.

B. What 2026 checklist should a foreign founder or company complete?

A foreign-led company should treat the grant as a controlled corporate and tax project. The following sequence is designed to identify an ineligible grant before the beneficiary pays an exercise price or signs a sale agreement.

1. Confirm the issuer and group perimeter. Identify the actual issuer, its legal form, its tax residence, its IS status, its RCS registration date and whether it is listed. If the issuer is foreign, verify the European Union or treaty connection, the administrative-assistance clause and the equivalent corporate-tax test. If the beneficiary works for a subsidiary or sub-subsidiary, draw the ownership chain and calculate the direct percentages required by the 2026 rule. Do not use a consolidated group percentage when the statute requires direct ownership, and do not assume that a commercial franchise or service agreement is a subsidiary.

2. Confirm the 15% capital condition and the origin of the business. Obtain the cap table as of the grant date and identify which holders are individuals, qualifying individual-owned entities or excluded investment vehicles. Check whether the company was formed through a restructuring, acquisition, extension or takeover of an existing business. If the company relies on an exception, put the legal and accounting analysis in the grant file. A later financing round, conversion or change in holding structure should trigger a fresh review for future grants.

3. Confirm the beneficiary’s legal role. Record whether the person is an employee of the issuer, an employee of a qualifying subsidiary, an officer subject to the salary-tax regime, a board member or a member of the equivalent SAS statutory body. For an SAS president or director who lives abroad, obtain the appointment decision, the articles provision supporting the office, the remuneration treatment and the evidence of actual functions. For an employee, align the employment contract, payroll entity, work location and grant schedule. A founder who is only an investor or contractor should be offered a different instrument or a different legal structure after advice; changing the label on the BSPCE schedule does not cure the role defect.

4. Obtain the corporate approvals before communication of a final grant. Prepare the EGM resolution, shareholder reports, delegation, board or president decision, beneficiary list and share-class description. The resolution should specify the maximum number of warrants, the subscription price or its legally authorised fixing mechanism, the exercise period, the share rights and the applicable terms. The beneficiary who is also a board member should not participate in the decision where the statutory conflict rule applies. Keep signed originals, electronic-signature evidence and the final version circulated to each beneficiary.

5. Build the plan for international mobility. The plan should define grant date, vesting dates, definitive acquisition date, exercise window, expiry, departure treatment, group transfers, good-leaver and bad-leaver events, death, sale, IPO and merger treatment. Add a practical document schedule for the foreign beneficiary: tax-residence certificates, work-location calendar, foreign payroll evidence, bank details, exchange-rate source, exercise notice, subscription bulletin and sale statement. The plan should tell the beneficiary that local law in the country of residence may tax an event earlier than France and may impose social-security contributions even if there is no immediate sale.

6. Verify the exercise price and valuation. Compare the price with any financing round in the six months before the grant. Explain differences between preferred shares and ordinary shares, liquidation preferences, conversion rights, voting rights and any material event after the financing. For an unlisted company, prepare a dated multi-criteria valuation at exercise and preserve the financial data used. If values are stated in dollars, pounds or another currency, retain the exchange-rate calculation into euros. The same record should show the number of shares, the class, the exercise price and the value used for the exercise gain.

7. Execute the subscription as a closing. The beneficiary should deliver the signed bulletin before the deadline, pay the exact price and receive an acknowledgment. The company should issue the shares, update the securities register and cap table, collect any accession to the shareholder agreement and give the beneficiary the documents needed by the foreign tax adviser. If payment is made through a foreign account or by set-off, document the legal basis and the actual settlement. A missing bulletin or missing payment can turn a seemingly valuable award into a disputed claim, as the Paris decisions cited above demonstrate.

8. Prepare the French and foreign tax filings before a sale. Separate the exercise gain from the post-exercise sale gain. Identify the French-source fraction by reference to the work and vesting history, check the residence at the relevant event, and read the treaty rather than relying on a domestic summary. Confirm who must withhold, who must receive the individual statement and whether the beneficiary must file form 2041-E or another return. The official Article 41 V bis of Annex III to the CGI sets the company’s information duties for BSPCE. The company should also prepare the information needed for the employee’s supplementary income-tax declaration and for the foreign country’s reporting.

9. Review a move, termination or group transfer before it occurs. Create a dated timeline showing the grant, each vesting or definitive-acquisition event, each period of work in France and abroad, the exercise date, the departure date, the tax-residence changes and the expected sale. Ask whether the person remains in an eligible office or employment relationship and whether the plan has a deadline after departure. Obtain written confirmation from the issuer before the person exercises. If the plan changes employing entities, verify whether the new entity is a qualifying subsidiary and whether the statutory activity period can be aggregated.

10. Audit the evidence after the transaction. The company should keep the eligibility memo, corporate approvals, plan, beneficiary acceptance, valuation, exercise bulletin, proof of payment, share issue record, tax forms, withholding calculation, work-location schedule and sale documents. The beneficiary should keep the same package, plus foreign returns, treaty forms, tax payments and evidence of credits claimed abroad. These documents matter if a bank asks for source-of-funds evidence, if a French tax office questions the 15% or 75% test, if a foreign authority recharacterises the gain or if an employment dispute follows termination.

Three recurring scenarios show why the sequence matters. First, a US founder who is the president of a French SAS and who remains resident in the United States may be eligible if the office and salary-tax conditions are satisfied and the French company meets the issuer tests. The French tax analysis then focuses on the French-source part of the exercise gain and the treaty’s employment-income rules; US reporting and possible US taxation must be assessed separately. Second, a UK parent may seek to grant instruments to personnel of a French subsidiary. The parent’s treaty and equivalent-tax status, the direct 75% ownership condition and the plan’s French-compliant approval process must be checked before the parent’s standard global plan is used. Third, a French employee may exercise after moving to Portugal. The tax-residence date, workdays during the reference period, French withholding, Portuguese tax at exercise or sale and the treaty credit mechanism must be coordinated before the exercise price is paid.

The commercial objective should be clear in every case: give the foreign founder or employee a real, documented participation right without creating an unexpected tax bill, a defective corporate issue or a cash-flow problem. The 2026 rules are sufficiently technical that the company should obtain a written eligibility and valuation record at grant, not reconstruct it years later when the shares are sold.

Conclusion

A French joint-stock company can grant BSPCE to a foreign founder or employee, and a qualifying foreign company can in some cases use the French regime as well. The result depends on the issuer, the capital and group tests, the beneficiary’s precise legal role, the EGM approval, the fixed exercise price and the evidence of each exercise. Foreign nationality is not the obstacle; an unqualified role, an incorrect group chain or an incomplete corporate file is.

For a 2026 grant or exercise, separate the exercise gain from the later sale gain, preserve the value and work-location history, review the three-year rule, and anticipate French withholding and the tax treaty before the beneficiary moves or sells. The plan, the corporate resolutions and the subscription bulletin should tell the same story. That consistency is the best protection for the company and the beneficiary.

Need a quick opinion on your case

A telephone consultation can be arranged within 48 hours with a lawyer from the firm.

We can review the BSPCE plan, the foreign-company documents, the exercise timetable and the cross-border tax question.

Phone: +33 6 46 60 58 22

Contact the firm about your French company and BSPCE matter.